[Edaily Reporter Kwon Oh Seok ] TiumBio Co., Ltd.(321550)announced on the 24th that CEO Kim Hoon-taek purchased 70,214 shares of the company’s stock on the open market.

The purchase took place over three trading days, from the 18th to the 22nd. The company explained that the CEO’s increase in his stake reflects his confidence in the growth potential of the company’s core pipeline and its future enterprise value.
TiumBio Co., Ltd. is currently advancing the development of its key clinical pipeline and pursuing global commercialization, centered on Merigolix (TU2670) and Tosfosertib (TU2218). Merigolix is an oral gonadotropin-releasing hormone (GnRH) antagonist intended for the treatment of endometriosis and uterine fibroids, and Tosfosertib is a dual inhibitor that simultaneously inhibits transforming growth factor beta (TGF-β) and vascular endothelial growth factor receptor 2 (VEGFR2) and is being developed primarily for use in combination with immuno-oncology therapies.
The company emphasized that these two pipeline candidates are demonstrating their potential as therapeutic agents by securing meaningful clinical data based on their respective “best-in-class” and “first-in-class” competitive advantages. Furthermore, given that discussions regarding various forms of collaboration—including technology transfer and joint development—are currently underway with global pharmaceutical and biotech companies, the company explained that there is significant potential for a revaluation of the pipeline’s value in the future.
A TiumBio Co., Ltd. official stated, “The CEO’s stock purchase is an expression of his commitment to responsible management aimed at enhancing shareholder value,” adding, “We will continue to increase the company’s value through the success of our clinical development and global commercialization efforts.”